Finance

Lists
BIIB34:BVMF
Biogen Inc BDR
186,01 R$
0,00%
(0,00) 1D
9 հոկ, 16:56:00 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for BIIB34...
Open
186,01 R$
High
186,01 R$
Low
186,01 R$
Mkt. cap
33,35 մլրդ
Avg. vol.
7,00
Volume
1,00
52-wk high
191,00 R$
52-wk low
128,69 R$
Shares outstanding
147,75 մլն
No. of employees
8 հզր
Open
186,01 R$
High
186,01 R$
Low
186,01 R$
Mkt. cap
33,35 մլրդ
Avg. vol.
7,00
Volume
1,00
52-wk high
191,00 R$
52-wk low
128,69 R$
Shares outstanding
147,75 մլն
No. of employees
8 հզր
News stories
From web sources and news partners
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc BDR
CEOChris Viehbacher
Employees7,5 հզր
Founded1978
HeadquartersՔեմբրիջ, Մասսաչուսեթս, Միացյալ Նահանգներ
Sector-
Websitebiogen.com
Last report
29 հլս, 2026 թ.
Fiscal period
Q2 2026
3,60 $ / 2,03 $
+77,38%beat
Revenue / Est. (USD)
2,74 մլրդ / 2,46 մլրդ
+11,19%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
2,53 մլրդ
2,28 մլրդ
2,48 մլրդ
2,74 մլրդ
Cost of goods sold
508,60 մլն
443,40 մլն
610,20 մլն
611,60 մլն
Cost of revenue
508,60 մլն
443,40 մլն
610,20 մլն
611,60 մլն
Research and development expenses
431,80 մլն
477,10 մլն
482,20 մլն
492,10 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
592,80 մլն
685,20 մլն
607,30 մլն
709,70 մլն
Operating expense
1,25 մլրդ
1,36 մլրդ
1,30 մլրդ
1,44 մլրդ
Total operating expenses
1,76 մլրդ
1,81 մլրդ
1,91 մլրդ
2,05 մլրդ
Operating income
778,60 մլն
471,60 մլն
567,40 մլն
685,60 մլն
Other non operating income
15,80 մլն
17,40 մլն
-1,10 մլն
3,00 մլն
EBT including unusual items
557,30 մլն
-56,00 մլն
377,70 մլն
132,40 մլն
EBT excluding unusual items
748,30 մլն
447,00 մլն
530,10 մլն
625,10 մլն
Income tax expense
90,80 մլն
-7,10 մլն
58,20 մլն
34,90 մլն
Effective tax rate
16,29%
12,68%
15,41%
26,36%
Other operating expenses
87,20 մլն
69,90 մլն
74,20 մլն
68,80 մլն
Net income
466,50 մլն
-48,90 մլն
319,50 մլն
97,50 մլն
Net profit margin
18,40%
-2,15%
12,89%
3,56%
Earnings per share
4,81
1,99
3,57
3,60
Interest and investment income
31,60 մլն
37,20 մլն
37,90 մլն
25,30 մլն
Interest expense
-67,40 մլն
-67,50 մլն
-67,60 մլն
-82,30 մլն
Net interest expenses
-35,80 մլն
-30,30 մլն
-29,70 մլն
-57,00 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
980,80 մլն
671,80 մլն
771,80 մլն
921,70 մլն
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google Apps